Trusted by 100,000+ International Patients
CAR-T: Malaysia vs Vietnam
Cost, Quality & Recovery Compared
$75000
Malaysia Starting Cost
$30000
Vietnam Starting Cost
See how these top medical tourism destinations compare for CAR-T.
| Comparison Factor | Malaysia | Vietnam | Winner |
|---|---|---|---|
| Average Cost (in USD) | 75000 - 125000 | 30000 - 50000 | Vietnam |
| Success Rate (Min and Max) | 60% – 85% response (indication dependent) | 50% – 75% response (indication dependent) | Malaysia |
| Advanced Technology | Emerging CAR-T therapy programmes in select leading oncology centres, supported by GMP-compliant cell processing collaborations, apheresis units, advanced molecular diagnostics, next-generation sequencing, and specialised haematology-oncology ICUs equipped to manage CRS and ICANS complications. | Emerging CAR-T therapy programs in select advanced oncology centres, supported by regional collaborations, apheresis units, molecular diagnostics, and early-stage cellular therapy infrastructure, with growing access to approved and clinical-trial CAR-T treatments | Both Equal |
| JCI Accredited Hospitals | 25+ | 1–3 | Malaysia |
| Visa Process | Medical Visa / eVisa / Social Visit Pass (2–5 working days; nationality dependent) | Medical Visa / E-visa / Tourist Visa (3–7 working days, faster processing) | Both Equal |
| Hospital Stay (typical) | 14–28 days | 14–28 days (depending on patient condition and monitoring needs) | Both Equal |
| Patient Journey Complexity | Very High (complex personalised immunotherapy involving cell harvesting, genetic modification, conditioning chemotherapy, and intensive monitoring) | High (requires specialised centres, eligibility screening, and close monitoring, though less complex than highly regulated Western programs) | Both Equal |
*Costs are estimates and may vary based on hospital, complexity, and package inclusions. See detailed cost breakdown below
Understand exactly where your money goes. Both countries offer all-inclusive packages, but here's how the costs typically break down.
Best for Budget-Conscious Patients
Offered Package Price (Additional Cost Excluded)
Best for Flexible Donor Requirements
Offered Package Price (Additional Cost Excluded)
Want a personalized cost estimate based on your specific condition?
Get Your Free QuoteBoth Malaysia and Vietnam maintain world-class healthcare standards with internationally accredited hospitals and highly trained medical professionals.
Malaysia hosts internationally accredited hospitals, including JCI-certified oncology centres, ensuring adherence to global standards in cancer care and emerging cellular therapies.
CAR-T therapy outcomes are evolving, with selected centres demonstrating encouraging response rates supported by advanced diagnostics and experienced haematology-oncology teams.
Healthcare is regulated by the Ministry of Health Malaysia (MOH), ensuring compliance with international safety, ethical, and clinical governance standards for advanced therapies.
Leading hospitals are approved by the Ministry of Health, with a few internationally accredited (e.g., Joint Commission International) and aligned to global quality standards.
Moderate to good outcomes in advanced therapies, with improving success rates supported by growing expertise and international collaborations.
Healthcare in Vietnam is regulated by the Ministry of Health, ensuring safety, ethical practices, and controlled adoption of advanced treatments.
| Quality Metric | Malaysia | Vietnam |
|---|---|---|
Accredited Hospitals | 25+ | 1–3 |
Average Success Rate | 60% – 80% response | 50% – 75% response (indication dependent) |
Post‑op / 1‑year outcome signal | Indication-dependent | Moderate to good remission outcomes in selected indications; improving with international collaborations |
Top Speciality Hubs | Kuala Lumpur | Hanoi, Ho Chi Minh City |
Both countries have highly qualified and experienced medical specialists trained at premier institutions worldwide. Here's what sets them apart.
Haematologists and oncology specialists trained in immunotherapy, stem cell transplantation, and advanced cancer treatments with growing expertise in CAR-T and cellular therapies.
Selected tertiary cancer centres manage complex haematological malignancies with multidisciplinary teams; CAR-T experience is developing compared to global leaders.
Trained haematologists and oncologists with experience in immunotherapy, stem cell transplantation, and emerging CAR-T protocols, often supported by international training and collaborations
Moderate experience in select tertiary centres, with growing exposure to CAR-T therapy through pilot programs, partnerships, and clinical research initiatives
All surgeons listed on Medigence are verified for their medical license, board certifications, hospital affiliations, and patient outcomes. We conduct background checks and regularly update our database to ensure you're connected with the best medical professionals.
Beyond medical excellence, your comfort during treatment matters. Compare the patient experience at top hospitals in both destinations.
World-class hospitals, exceptional value
Advanced oncology centres equipped with apheresis units, specialised haematology wards, transplant units, ICU facilities, and access to GMP-compliant labs through regional or international collaborations.
Luxury healthcare experience
Modern oncology centres equipped with apheresis units, molecular diagnostics, ICU support, and developing cellular therapy labs, with some hospitals collaborating internationally for CAR-T processing and delivery
Plan your medical journey with confidence. Here's everything you need to know about travel, visas, and accommodation in both countries.
We provide end-to-end travel assistance including visa facilitation, airport pickups, hotel bookings near your hospital, and local support throughout your stay. Our patient coordinators handle all logistics so you can focus on recovery.
Understanding the recovery process helps you plan better. Here's what to expect after CAR-T in both countries.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to remain near the treatment centre for regular monitoring, blood tests, and immediate management of any complications that arise.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
In-person follow-ups recommended at 3, 6, 12 months. Telemedicine available.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to remain near the treatment centre for regular monitoring, blood tests, and immediate management of any complications that arise.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
Comprehensive telemedicine follow-up program. Return visits at 6, 12 months if possible.
CAR-T recipients require lifelong immunosuppressant medications. Ensure you have a plan for obtaining these medications and regular blood monitoring in your home country before traveling abroad for surgery.
Every medical procedure carries risks. We believe in complete transparency so you can make a fully informed decision about your CAR-T journey.
An immune reaction after CAR-T infusion causes fever, low blood pressure, and flu-like symptoms.
Temporary neurological symptoms such as confusion, headache, or speech difficulty may occur.
The weakened immune system after therapy increases the risk of bacterial or viral infections.
Reduced levels of red cells, white cells, or platelets may increase the risk of infection or bleeding.
Side effects may occur due to supportive medications, such as chemotherapy or immune-related treatments, used during CAR-T therapy.
The right choice depends on your specific situation. Here's a clear guide to help you decide which destination aligns with your needs.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Our medical tourism experts can analyze your case and recommend the best destination based on your medical history and budget.
Follow this step-by-step framework to make the right choice for your CAR-T journey.
Assess the type and stage of cancer to determine eligibility and urgency for CAR-T therapy.
Plan the overall cost, including treatment, travel, accommodation, and unexpected medical expenses.
Ensure you can stay near the treatment centre for monitoring during the early recovery period.
Provide detailed reports in advance so specialists can evaluate eligibility and create a treatment plan.
Arrange continued monitoring and coordination with local doctors for recovery and long-term outcomes.
Let our medical tourism experts guide you through the process. We'll help you:
No obligation • Free consultation • Response within 24 hours
Surgical Oncologist
15 Years of Experience
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More
